Abnormalities of the ARF-p53 pathway in primary angiosarcomas of the liver

被引:31
作者
Weihrauch, M
Markwarth, A
Lehnert, G
Wittekind, C
Wrbitzky, R
Tannapfel, A
机构
[1] Univ Hannover, Inst Occupat Med, Hannover, Germany
[2] Univ Leipzig, Inst Pathol, Leipzig, Germany
[3] Univ Erlangen Nurnberg, Inst Occupat Social & Environm Med, Erlangen, Germany
关键词
angiosarcoma; vinyl chloride; p14(ARF); p16(INK4); p53; histopathology; methylation;
D O I
10.1053/hupa.2002.126880
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The INK4a-ARF locus, located on chromosome 9p21, encodes 2 cell cycle-regulatory proteins, p16(INKa) and p14(ARF), acting through the Rb-CDK4 and p53 pathways. This study was done to investigate the contribution of the INK4a-ARF locus in tumorigenesis of angiosarcoma of the liver. Alterations of p14(ARF), p16(INKa), and p53 in primary Ever angiosarcoma from 19 patients were analyzed by methylation-specific polymerase chain reaction (MSP), restriction enzyme-related polymerase chain reaction (RE-PCR), microsatellite analysis, and DNA sequencing. As a control group, 12 angiosarcomas from other organs were analyzed. Promoter methylation of p14(ARF) was found in 5 of 19 cases (26%), and p16(INKa) showed aberrant promoter methylation in 12 of 19 cases (63%). One tumor (5%) had homozygous deletion of the INK4a-ARF locus. Methylation and deletion correlated with loss of mRNA transcription. Methylated p14(ARF) appeared in the context of a methylated p16(INKa) promoter in 3 cases of the 5 angiosarcomas methylated at p14(ARF). p14(ARF) aberrant methylation was not related to the presence of p53 mutations, which was detected in 6 of 19 (32%) cases. Alterations of the INK4a-ARF locus or p53 as were not established independent prognostic factors in these tumors. In conclusion, our data indicate that the INK4a-ARF locus is frequently inactivated in angiosarcoma of the liver and occurs independently of p53 mutations. Copyright 2002, Elsevier Science (USA). All rights reserved.
引用
收藏
页码:884 / 892
页数:9
相关论文
共 25 条
[1]   Frequent methylation silencing of p15INK4b (MTS2) and p16INK4a (MTS1) in B-cell and T-cell lymphomas [J].
Baur, AS ;
Shaw, P ;
Burri, N ;
Delacrétaz, F ;
Bosman, FT ;
Chaubert, P .
BLOOD, 1999, 94 (05) :1773-1781
[2]   Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma [J].
Bradley, G ;
Irish, J ;
MacMillan, C ;
Mancer, K ;
Witterick, I ;
Hartwick, W ;
Gullane, P ;
Kamel-Reid, S ;
Benchimol, S .
ONCOGENE, 2001, 20 (05) :654-658
[3]   Analysis of chromosome 9p21 deletion and p16 gene mutation in salivary gland carcinomas [J].
Cerilli, LA ;
Swartzbaugh, JR ;
Saadut, R ;
Marshall, CE ;
Rumpel, CA ;
Moskaluk, CA ;
Frierson, HF .
HUMAN PATHOLOGY, 1999, 30 (10) :1242-1246
[4]   Germ-line mutations of the p16(INK4)(MTS1) gene occur in a subset of patients with hepatocellular carcinoma [J].
Chaubert, P ;
Gayer, R ;
Zimmermann, A ;
Fontolliet, C ;
Stamm, B ;
Bosman, F ;
Shaw, P .
HEPATOLOGY, 1997, 25 (06) :1376-1381
[5]   p16INK4a expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation [J].
Dai, CY ;
Furth, EE ;
Mick, R ;
Koh, J ;
Takayama, T ;
Niitsu, Y ;
Enders, GH .
GASTROENTEROLOGY, 2000, 119 (04) :929-942
[6]  
Esteller M, 2000, CANCER RES, V60, P129
[7]   Liver pathology: Cirrhosis, hepatitis, and primary liver tumors. update and diagnostic problems [J].
Ferrell, L .
MODERN PATHOLOGY, 2000, 13 (06) :679-704
[8]   p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma [J].
Fulci, G ;
Labuhn, M ;
Maier, D ;
Lachat, Y ;
Hausmann, O ;
Hegi, ME ;
Janzer, RC ;
Merlo, A ;
Van Meir, EG .
ONCOGENE, 2000, 19 (33) :3816-3822
[9]   Liver angiosarcoma and hemangiopericytoma after occupational exposure to vinyl chloride monomer [J].
Hozo, I ;
Miric, D ;
Bojic, L ;
Giunio, L ;
Lusic, I ;
Culic, V ;
Simunic, M .
ENVIRONMENTAL HEALTH PERSPECTIVES, 2000, 108 (08) :793-795
[10]   Human ARF protein interacts with Topoisomerase I and stimulates its activity [J].
Karayan, L ;
Riou, JF ;
Séité, P ;
Migeon, J ;
Cantereau, A ;
Larsen, CJ .
ONCOGENE, 2001, 20 (07) :836-848